Wanbury growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+8.5%+4.1%+15.2%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+39.9%+9.0%+202.1%
+46.7%+10.6%+428.1%
+116.6%+0.4%+392.4%
+120.5%+0.3%+250.3%
+25.1%+20.5%+13.6%
+143.7%+112.1%+484.9%
+20.8%+549.8%−79.7%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

WANBURY₹181.93

Wanbury Limited

· Pharma & Health
₹ CrorePeersAHCLANUHPHRBAJAJHCARETHEMISMEDZIMLABLINCOLNSIGACHIVALIANTLABMcap ₹636 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+15.2+4.1+8.5—
EBITDA Growth—+202.1+9.0+39.9—
EBIT Growth—+428.1+10.6+46.7—
Net Income Growth—+392.4+0.4+116.6—
EPS Growth—+250.3+0.3+120.5—
Total Assets Growth—+13.6+20.5+25.1—
Total Equity Growth—+484.9+112.1+143.7—
Cash from Operations Growth—-79.7+549.8+20.8—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.